Skip to main content
Erschienen in: Supportive Care in Cancer 2/2019

06.07.2018 | Original Article

IMproved MAnagement (IM-MA study) in cancer-related pain: the value of a joint approach by an integrated team of radiotherapist and anesthetist

verfasst von: S. Manfrida, V. Masiello, F. Cellini, E. Adducci, L. Polidori, S. Longo, G. Cannelli, M. Balducci, M. Rossi, V. Valentini

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Purpose of this study was to retrospectively review our experience of multidisciplinary clinic providing a joint approach by radiation oncologist and anesthetist for patients with cancer pain to evaluate the adequacy and the IMprovement in MAnagement (IM-MA study) of this symptom.

Methods

A Team for Pain Management (TPM) represented by radiation oncologist and anesthetist weekly provided consultations to patient presenting cancer pain. TPM prospectively reported epidemiologic, symptomatic, and pharmacological data. TPM modified pain therapy and indicated antalgic radiotherapy. Patients were evaluated at baseline and after 4 weeks after intervention.

Results

From November 2015 to April 2016, 65 patients were evaluated by TPM. At the baseline, 18 patients (27.7%) were undertreated (i.e., receiving inadequate pain management); furthermore, 27 patients (41.5%) despite receiving strong opioids had uncontrolled pain. After 4 weeks from intervention, undertreated patients were reduced to 1.53%. For those patients undergone to radiotherapy, response at 34 weeks was scored as follows: complete response 28.8%, partial response 46.7%, pain progression 0.95%, indeterminate response 23.8%.

Conclusions

A multidisciplinary Team for Pain Management improved the clinical management, optimizing pain control and increasing adequacy of pharmacological management. The TPM intervention seems particularly worth for patients presenting specific features including BTcP, neuropathic pain, severe pain due to bone metastases, and any potential candidate to radiotherapy. Larger series and QoL questionnaires are required to confirm these results.
Literatur
1.
Zurück zum Zitat Mitera G, Fairchild A, DeAngelis C, Emmenegger U, Zurawel-Balaura L, Zhang L, Bezjak A, Levin W, Mclean M, Zeiadin N, Pang J, Nguyen J, Sinclair E, Chow E, Wong R (2010) A multicenter assessment of the adequacy of cancer pain treatment using the pain management index. J Palliat Med 13(5):589–593. https://doi.org/10.1089/jpm.2009.0342 CrossRefPubMed Mitera G, Fairchild A, DeAngelis C, Emmenegger U, Zurawel-Balaura L, Zhang L, Bezjak A, Levin W, Mclean M, Zeiadin N, Pang J, Nguyen J, Sinclair E, Chow E, Wong R (2010) A multicenter assessment of the adequacy of cancer pain treatment using the pain management index. J Palliat Med 13(5):589–593. https://​doi.​org/​10.​1089/​jpm.​2009.​0342 CrossRefPubMed
2.
Zurück zum Zitat Van den Beuken-van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449CrossRef Van den Beuken-van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449CrossRef
3.
Zurück zum Zitat World Health Organization, Cancer pain relief (1996) with a guide to opioid availability, 2nd edn. Geneva, Switzerland World Health Organization, Cancer pain relief (1996) with a guide to opioid availability, 2nd edn. Geneva, Switzerland
4.
Zurück zum Zitat Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC) (2012) Use of opioids in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2 CrossRef Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC) (2012) Use of opioids in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68. https://​doi.​org/​10.​1016/​S1470-2045(12)70040-2 CrossRef
5.
Zurück zum Zitat Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154CrossRef Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154CrossRef
6.
Zurück zum Zitat Ripamonti CI (2012) Pain management. Ann Oncol 23(Suppl 10):294–301CrossRef Ripamonti CI (2012) Pain management. Ann Oncol 23(Suppl 10):294–301CrossRef
8.
Zurück zum Zitat Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A (1998) Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manag 16(3):171–178CrossRef Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A (1998) Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manag 16(3):171–178CrossRef
10.
Zurück zum Zitat Massaccesi M, Deodato F, Caravatta L, Macchia G, Padula GD, Di Rito S, Woldemariam AA, Rossi M, Di Falco C, Tambaro R, Mignogna S, Flocco M, Pacelli F, Valentini V, Cellini N, Morganti AG (2013) Incidence and management of noncancer pain in cancer patients referred to a radiotherapy center. Clin J Pain 29(11):944–947CrossRef Massaccesi M, Deodato F, Caravatta L, Macchia G, Padula GD, Di Rito S, Woldemariam AA, Rossi M, Di Falco C, Tambaro R, Mignogna S, Flocco M, Pacelli F, Valentini V, Cellini N, Morganti AG (2013) Incidence and management of noncancer pain in cancer patients referred to a radiotherapy center. Clin J Pain 29(11):944–947CrossRef
11.
Zurück zum Zitat Yau V, Chow E, Davis L, Holden L, Schueller T, Danjoux C (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manag 27(1):1–3CrossRef Yau V, Chow E, Davis L, Holden L, Schueller T, Danjoux C (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manag 27(1):1–3CrossRef
15.
Zurück zum Zitat Nieder C, Dalhaug A, Pawinski A, Haukland E, Mannsåker B, Engljähringer K (2015) Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team: a retrospective comparison. Radiat Oncol 10(61). https://doi.org/10.1186/s13014-015-0365-0 Nieder C, Dalhaug A, Pawinski A, Haukland E, Mannsåker B, Engljähringer K (2015) Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team: a retrospective comparison. Radiat Oncol 10(61). https://​doi.​org/​10.​1186/​s13014-015-0365-0
17.
Zurück zum Zitat Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 63(Suppl 11):S240–S252. https://doi.org/10.1002/acr.20543 CrossRef Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 63(Suppl 11):S240–S252. https://​doi.​org/​10.​1002/​acr.​20543 CrossRef
18.
Zurück zum Zitat Li KK, Harris K, Hadi S, Chow E (2007) What should be the optimal cutpoints for mild, moderate and severe pain? J Palliat Med 10(6):1338–1346CrossRef Li KK, Harris K, Hadi S, Chow E (2007) What should be the optimal cutpoints for mild, moderate and severe pain? J Palliat Med 10(6):1338–1346CrossRef
19.
Zurück zum Zitat Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284CrossRef Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284CrossRef
21.
Zurück zum Zitat Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64(3):275–280CrossRef Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64(3):275–280CrossRef
22.
Zurück zum Zitat Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E (2012) International Bone Metastases Consensus Working Party. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 82(5):1730–1737. https://doi.org/10.1016/j.ijrobp.2011.02.008 CrossRefPubMed Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E (2012) International Bone Metastases Consensus Working Party. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 82(5):1730–1737. https://​doi.​org/​10.​1016/​j.​ijrobp.​2011.​02.​008 CrossRefPubMed
24.
Zurück zum Zitat Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330(9):592–596CrossRef Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330(9):592–596CrossRef
26.
27.
Zurück zum Zitat Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group (CPOR SG) Investigators (2009) Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 100:1566–1574CrossRef Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group (CPOR SG) Investigators (2009) Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 100:1566–1574CrossRef
Metadaten
Titel
IMproved MAnagement (IM-MA study) in cancer-related pain: the value of a joint approach by an integrated team of radiotherapist and anesthetist
verfasst von
S. Manfrida
V. Masiello
F. Cellini
E. Adducci
L. Polidori
S. Longo
G. Cannelli
M. Balducci
M. Rossi
V. Valentini
Publikationsdatum
06.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4335-6

Weitere Artikel der Ausgabe 2/2019

Supportive Care in Cancer 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.